Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin as a first line treatment for the management of metastatic pancreatic adenocarcinoma: A budget impact analysis from a US payer perspective

被引：0
|
作者：
Kim, George P.
Holland, Theo
Patrick, Caity
Lewis, Megan
Cockrum, Paul
Eddy, Alexandra
机构：
[1] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL USA
[2] FIECON, London, England
[3] Ipsen, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16339
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1/2 study
    Dean, Andrew
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Macarulla, Teresa
    Mody, Kabir
    Belanger, Bruce
    Maxwell, Fiona
    Moore, Yan
    Thiagalingam, Arunthathi
    Wang, Tiffany
    Zhang, Bin
    Wainberg, Zev A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 118 - 119
  • [2] NALIRIFOX (iposomal irinotecan+5-fluorouracil/feucovorin plus oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin plus oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
    O'Reilly, E.
    Li, J.
    DerSarkissian, M.
    Chang, R.
    Cheng, M.
    Yu, L.
    Rane, D.
    Zhang, L.
    Xiao, Z.
    Benzaghou, F.
    Duh, M.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S83 - S83
  • [3] nITRO: A phase 2 study of perioperative liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
    Melisi, Davide
    Zecchetto, Camilla
    Merz, Valeria
    Malleo, Giuseppe
    Landoni, Luca
    Quinzii, Alberto
    Casalino, Simona
    Gaule, Marina
    Pesoni, Camilla
    Casetti, Luca
    Esposito, Alessandro
    Piazzola, Cristiana
    D'Onofrio, Mirko
    de Robertis, Riccardo
    Gabbrielli, Armando
    Luchini, Claudio
    Butturini, Giovanni
    Scarpa, Aldo
    Salvia, Roberto
    Bassi, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 701 - 701
  • [4] Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
    Wainberg, Z.
    Melisi, D.
    Macarulla, T.
    Cid, R. Pazo
    Chandana, S.
    de la Fouchardiere, C.
    Dean, A.
    Kiss, I.
    Lee, W.
    Goetze, T.
    Van Cutsem, E.
    Paulson, S.
    Bekaii-Saab, T.
    Pant, S.
    Hubner, R.
    Xiao, Z.
    Chen, H.
    Benzaghou, F.
    O'Reilly, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S180 - S180
  • [5] First-line liposomal irinotecan+5 fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
    Dean, A.
    Bekaii-Saab, T.
    Boland, P. M.
    Dayyani, F.
    Macarulla Mercade, T.
    Mody, K.
    Belanger, B.
    Maxwell, F.
    Moore, Y.
    Thiagalingam, A.
    Wang, T.
    Zhang, B.
    Wainberg, Z. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1314
  • [6] FOLFOX (oxaliplatin and leucovorin plus fluorouracil) versus FOLFIRI (irinotecan and leucovorin plus fluorouracil) chemotherapy as a first-line treatment in a patients with unresectable metastatic or recurred gastric adenocarcinoma
    Tak, Dae Hyun
    Kim, Seok Hyun
    Moon, Hee Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 261 - 261
  • [7] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Dean, Andrew
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Cutsem, Eric V.
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
  • [8] First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study
    Wainberg, Zev A.
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Macarulla, Teresa
    Mody, Kabir
    Belanger, Bruce
    Maxwell, Fiona
    Moore, Yan
    Thiagalingam, Arunthathi
    Wang, Tiffany
    Zhang, Bin
    Dean, Andrew
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 14 - 24
  • [9] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Van Cutsem, Eric
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Assaf, Elias
    Verlinde-Carvalho, Muriel
    Delbaldo, Catherine
    Grenier, Julien
    Sellam, Zineb
    Pouessel, Damien
    Bouaita, Linda
    Baumgaertner, Isabelle
    Sobhani, Iradj
    Tayar, Claude
    Paul, Muriel
    Culine, Stephane
    ONCOLOGY, 2011, 80 (5-6) : 301 - 306
12345